Prescription Drugs - Poland

Poland

In Poland, the Prescription Drugs market is anticipated to achieve a revenue of €2.17bn by 2024.
It is estimated that the market will experience a compound annual growth rate (CAGR 2024-2029) of 2.71%, leading to a market volume of €2.48bn by 2029.
When compared on a global scale, United States is projected to generate the highest revenue in the Prescription Drugs market, amounting to €329.40bn in 2024.
In terms of per capita revenue, each person in Poland is expected to generate €54.06 in 2024.
Poland's prescription drug market is witnessing a surge in demand for generic medications due to their cost-effectiveness and widespread availability.

Key regions: Japan, China, Europe, Australia, Canada

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The Prescription Drugs (Pharmacies) market in Poland has been experiencing significant growth in recent years. Customer preferences for prescription drugs have been influenced by various factors, leading to changes in the market. Additionally, local special circumstances and underlying macroeconomic factors have also played a role in shaping the trends in the market.

Customer preferences: In Poland, customers have shown a growing preference for prescription drugs due to an aging population and an increasing prevalence of chronic diseases. As the population ages, the demand for medications to manage and treat these conditions has risen. Furthermore, increased awareness and access to healthcare services have also contributed to the growing demand for prescription drugs.

Trends in the market: One of the key trends in the Prescription Drugs (Pharmacies) market in Poland is the shift towards online pharmacies. With the advancement of technology and the convenience it offers, more customers are turning to online platforms to purchase their prescription drugs. This trend has been further accelerated by the COVID-19 pandemic, which has led to an increased reliance on e-commerce and contactless transactions. Another trend in the market is the growing demand for generic drugs. Generic drugs are more affordable alternatives to brand-name medications, and customers in Poland are increasingly opting for these cost-effective options. This trend can be attributed to the rising healthcare costs and the efforts of the government to promote the use of generic drugs to reduce healthcare expenditure.

Local special circumstances: Poland has a well-established healthcare system that provides universal healthcare coverage to its citizens. This has contributed to the demand for prescription drugs as patients have access to subsidized medications. Additionally, the presence of a large number of pharmacies across the country ensures easy accessibility to prescription drugs for the population.

Underlying macroeconomic factors: The growing Prescription Drugs (Pharmacies) market in Poland can be attributed to several macroeconomic factors. The country has experienced steady economic growth in recent years, which has led to an increase in disposable income. This, in turn, has allowed individuals to spend more on healthcare, including prescription drugs. Furthermore, government initiatives and policies aimed at improving healthcare infrastructure and services have also played a role in the development of the market. The government has implemented measures to ensure the availability and affordability of prescription drugs, thereby driving the demand in the market. In conclusion, the Prescription Drugs (Pharmacies) market in Poland has been growing due to customer preferences for prescription drugs, the emergence of online pharmacies, and the demand for generic drugs. Local special circumstances, such as the well-established healthcare system and the presence of numerous pharmacies, have also contributed to the market's development. Additionally, underlying macroeconomic factors, including economic growth and government initiatives, have played a significant role in shaping the trends in the market.

Methodology

Data coverage:

The data encompasses B2C enterprises. Figures are based on offline and online spending by consumers, including VAT. Not included are B2B and B2G sales, or other pharmaceutical sales through hospitals or retail stores such as supermarkets.

Modeling approach:

Market sizes are determined through a bottom-up approach, building on specific predefined factors for each market market. As a basis for evaluating markets, we use industry associations, third-party studies and reports and survey results from our primary research (e.g., the Statista Global Consumer Survey). In addition, we use relevant key market indicators and data from country-specific associations, such as healthcare expenditure per country, consumer healthcare spending, GDP and internet penetration. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the relevant market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. For forecasting digital trends such as the online-pharmacy sales share we use exponential trend smoothing and the s-curve method. The main drivers are healthcare expenditure per country and consumer healthcare spending.

Additional notes:

The data is modeled using current exchange rates. The impact of the COVID-19 pandemic and the Russia-Ukraine war are considered at a country-specific level. The market is updated twice a year. GCS data is reweighted for representativeness.